Atahan, LaleYıldız, FerahCengiz, MustafaKaplan, BünyaminÖzkan, MetinYazıcı, GözdeGündoğ, MeteHaydaroğlu, AyferKorcum, Aylin FidanŞengöz, MeriçDinçer, MaktavAkmansu, MügeHayran, Mutlu2022-09-082022-09-082010-06Atahan, L. vd. (2010). "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study". Supportive Care in Cancer, 18(6), 691-698.0941-43551433-7339https://doi.org/10.1007/s00520-009-0663-xhttps://link.springer.com/article/10.1007/s00520-009-0663-xhttp://hdl.handle.net/11452/28552In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated. Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated. No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.eninfo:eu-repo/semantics/closedAccessBone metastasisBreast cancerRadiotherapyZoledronic acidIn-vitroSkeletal complicationsMultifraction radiotherapyBisphosphonates inhibitTrialCarcinomaCellsApoptosisAdhesionSingleOncologyHealth care sciences & servicesRehabilitationAdultAgedAged, 80 and overBone density conservation agentsBone neoplasmsBreast neoplasmsCombined modality therapyDiphosphonatesFemaleHumansImidazolesKaplan-Meiers estimateMiddle agedPain measurementPalliative careRadiotherapy dosageArticle0002779428000052-s2.0-7795362132769169818619484483OncologyHealth care sciences & servicesRehabilitationZoledronic Acid; Bone Metastasis; Bisphosphonic Acid DerivativeAlkaline phosphataseZoledronic acidBisphosphonic acid derivativeBone density conservation agentImidazole derivativeZoledronic acidAdultAgedAlkaline phosphatase blood levelArticleBone metastasisBone scintiscanningBreast cancerCancer chemotherapyCancer palliative therapyCancer patientCancer radiotherapyClinical effectivenessClinical studyClinical trialDiarrheaDyspepsiaFemaleFlu like syndromeHumanMajor clinical studyMultimodality cancer therapyNauseaNuclear magnetic resonance imagingOutcome assessmentPain assessmentPatient safetyPatient satisfactionPhase 4 clinical trialPriority journalRadiation doseTreatment responseUrinary tract infectionVisual analog scaleWhole body scintiscanningBone neoplasmsBreast neoplasmsControlled studyKaplan Meier methodMiddle agedMultimodality cancer therapyPain measurementPalliative therapyPathologyRandomized controlled trialSecondaryVery elderly